Prospective Treatment Algorithm Guiding Repair of Severe Ischemic Mitral Regurgitation
1 other identifier
interventional
110
1 country
1
Brief Summary
Ischemic mitral regurgitation is a disease where the mitral valve is regurgitant, or leaking, as a result of changes in the muscle of the heart caused by coronary artery disease Ischemic mitral regurgitation, or IMR, is normally treated by repairing or replacing the mitral valve. Currently, we don't have very strong evidence showing which patients might benefit from mitral valve repair and which might benefit from replacement, and surgeons tend to repair or replace valves based on their preference or experience. Some surgeons, including Dr. Vincent Chan, the Principal Investigator, believe that the decision to repair or replace the valve should be based on specific measurements of the mitral valve. This study will randomly assign patients to receive either the current standard of care for ischemic mitral regurgitation, which is valve repair or replacement based on the surgeon's preference, or to have their treatment decided by a set of criteria called an algorithm. This algorithm will assign patients with certain mitral valve measurements to repair, and others to replacement. Patients will be followed for 12 months after surgery, to compare whether patients whose treatment was decided by the algorithm did better than patients whose treatment was decided by surgeon preference.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2017
CompletedFirst Posted
Study publicly available on registry
September 25, 2017
CompletedStudy Start
First participant enrolled
January 16, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2028
May 1, 2026
April 1, 2026
10.8 years
September 20, 2017
April 29, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Left ventricle end-systolic volume indexed to body surface area
Comparison of changes in the indexed volume of the left ventricle.
12 months after surgery
Secondary Outcomes (3)
Change in indexed left atrial volume
Up to 12 months after surgery
Change in right ventricle systolic pressure
Up to 12 months after surgery
Major adverse events
Up to 12 months after surgery
Study Arms (2)
Treatment algorithm
EXPERIMENTALMitral valve will be replaced if posterior leaflet tethering angle \>=25 degrees. Mitral valve will be repaired if posterior leaflet tethering angle \<25 degrees
No treatment algorithm
ACTIVE COMPARATORMitral valve will be repaired or replaced at surgeon's discretion.
Interventions
Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle \>=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.
Patients will have their valve repaired or replaced at the discretion of their surgeon.
Eligibility Criteria
You may qualify if:
- Severe ischemic mitral valve regurgitation
- years of age, and able to provide informed consent.
You may not qualify if:
- Mixed mitral valve pathology
- Acute ischemic mitral regurgitation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y4W7, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vincent Chan, MD
Ottawa Heart Institute Research Corporation
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Echocardiographic outcome assessment will be blinded.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 20, 2017
First Posted
September 25, 2017
Study Start
January 16, 2018
Primary Completion (Estimated)
November 1, 2028
Study Completion (Estimated)
November 1, 2028
Last Updated
May 1, 2026
Record last verified: 2026-04